Trevi Therapeutics Inc (NAS:TRVI)

$ 4.27 0.06 (1.43%) Market Cap: 376.23 Mil Enterprise Value: 293.08 Mil PE Ratio: 0 PB Ratio: 5.38 GF Score: 40/100

Q3 2024 Trevi Therapeutics Inc Earnings Call Transcript
Nov 06, 2024

$3.1 (+2.65%)

Earnings
Q2 2024 Trevi Therapeutics Inc Earnings Call Transcript
Aug 08, 2024

$2.8 (+8.11%)

Earnings
Q1 2024 Trevi Therapeutics Inc Earnings Call Transcript
May 07, 2024

$2.9 (-1.36%)

Earnings
Q4 2023 Trevi Therapeutics Inc Earnings Call Transcript
Mar 20, 2024

$3.54 (+2.31%)

Earnings
Q3 2023 Trevi Therapeutics Inc Earnings Call Transcript
Nov 09, 2023

$1.36 (-4.58%)

Earnings
Q2 2023 Trevi Therapeutics Inc Earnings Call Transcript
Aug 10, 2023

$2.39 (+3.46%)

Earnings
Q1 2023 Trevi Therapeutics Inc Earnings Call Transcript
May 11, 2023

$3 (+3.45%)

Earnings
Trevi Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 17, 2023
Q4 2022 Trevi Therapeutics Inc Earnings Call Transcript
Mar 16, 2023

$1.81 (-1.09%)

Earnings
Trevi Therapeutics Inc at Emerging Growth Conference Transcript
Feb 22, 2023
Q3 2022 Trevi Therapeutics Inc Earnings Call Transcript
Nov 10, 2022

$1.93

Earnings
Trevi Therapeutics Inc R&D Day (Virtual) Transcript
Sep 19, 2022
Q2 2022 Trevi Therapeutics Inc Earnings Call Transcript
Aug 11, 2022

$4.27 (+0.23%)

Earnings
Trevi Therapeutics Inc Haduvio PRISM Ph2b/3 Data Call Transcript
Jun 29, 2022
Q1 2022 Trevi Therapeutics Inc Earnings Call Transcript
May 12, 2022

$2.05 (+3.54%)

Earnings
Trevi Therapeutics Inc at Needham Healthcare Conference Transcript
Apr 12, 2022
Trevi Therapeutics Inc Understanding the Seriousness of Chronic Cough in IPF Patients and Trevi's Latest Data Webinar Transcript
Mar 30, 2022
Q4 2021 Trevi Therapeutics Inc Earnings Call Transcript
Mar 17, 2022

$1.53 (+4.79%)

Earnings
Trevi Therapeutics Inc Ph2 CANAL Interim Analysis Conference Call Transcript
Feb 24, 2022
Q3 2021 Trevi Therapeutics Inc Earnings Call Transcript
Nov 10, 2021

$1.17 (-1.68%)

Earnings
Q2 2021 Trevi Therapeutics Inc Earnings Call Transcript
Aug 12, 2021

$2.1 (+1.45%)

Earnings
Q1 2021 Trevi Therapeutics Inc Earnings Call Transcript
May 13, 2021

$2.01 (-6.51%)

Earnings
Q4 2020 Trevi Therapeutics Inc Earnings Call Transcript
Mar 25, 2021

$2.52 (-3.45%)

Earnings
Q3 2020 Trevi Therapeutics Inc Earnings Call Transcript
Nov 11, 2020

$3.82 (+14.94%)

Earnings
Q2 2020 Trevi Therapeutics Inc Earnings Call Transcript
Aug 13, 2020

$5.66 (-14.24%)

Earnings

Trevi Therapeutics Inc R&D Day (Virtual) Transcript

Sep 19, 2022 / 02:00PM GMT

Release Date Price: $3.06 (-6.13%)

Transcript

Operator

Good morning, and welcome to the Trevi Therapeutics R&D Day. (Operator Instructions). As a reminder, this call is being recorded and a replay will be made available on the Trevi website following the conclusion of the event. I'd now like to turn the call over to Katie McManus, Communications Manager at Trevi Therapeutics. Please go ahead, Katie.

Katie McManus

Good morning, and welcome to Trevi Therapeutics R&D Day. Various remarks that management makes during this call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in Risk Factors section of the company's most recent quarterly report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission and then subsequent filings with the Security and Exchange Commission

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.